A label revision for Dapagliflozin was announced by the FDA, effective 2026-05-18. The updated "INDICATIONS AND USAGE" section now includes a specific indication: to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus who have either established cardiovascular disease or multiple cardiovascular risk factors.
Background
Dapagliflozin, a medication used in the management of type 2 diabetes mellitus, has received an important label update. This revision formally recognizes its role beyond glycemic control, specifically addressing cardiovascular outcomes. The new indication targets a critical area of patient care by focusing on adults with type 2 diabetes who face an elevated risk of heart failure hospitalization. This population is defined by the presence of either established cardiovascular disease or multiple cardiovascular risk factors, highlighting the drug's expanded utility in a high-risk demographic.
What this means
This significant label update provides clear guidance for clinicians on the expanded use of Dapagliflozin for cardiovascular protection. The inclusion of reducing the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors means that healthcare providers can now prescribe Dapagliflozin with a dual therapeutic objective. This allows for more comprehensive patient management strategies, integrating both glycemic control and a specific, evidence-based intervention to mitigate heart failure risk in this vulnerable population. For researchers, this update reinforces the growing understanding of the cardiorenal benefits of certain diabetes medications. Patient advocates will find this an important development, as it offers an additional treatment option to address a major and often debilitating complication associated with type 2 diabetes, potentially improving quality of life and reducing healthcare burden. The formal recognition by the FDA underscores the importance of this specific benefit for patient care.
Source
The information regarding this label revision was obtained from the FDA, as detailed in an official document available on dailymed.nlm.nih.gov, effective 2026-05-18. The specific update is found within the "1 INDICATIONS AND USAGE" section of the drug's label, identified by the set ID c4264ff6-5199-49e9-91d3-3ad67b42f88d.